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Abstract: Aldosterone producing adenoma and bilateral adrenal hyperplasia are the two most
common subtypes of primary aldosteronism (PA) that require targeted and distinct therapeutic
approaches: unilateral adrenalectomy or lifelong medical therapy with mineralocorticoid receptor
antagonists. According to the 2016 Endocrine Society Guideline, adrenal venous sampling (AVS) is
the gold standard test to distinguish between unilateral and bilateral aldosterone overproduction and
therefore, to safely refer patients with PA to surgery. Despite significant advances in the optimization
of the AVS procedure and the interpretation of hormonal data, a standardized protocol across centers
is still lacking. Alternative methods are sought to either localize an aldosterone producing adenoma
or to predict the presence of unilateral disease and thereby substantially reduce the number of patients
with PA who proceed to AVS. In this review, we summarize the recent advances in subtyping PA for
the diagnosis of unilateral and bilateral disease. We focus on the developments in the AVS procedure,
the interpretation criteria, and comparisons of the performance of AVS with the alternative methods
that are currently available.
Keywords: aldosterone; primary aldosteronism; adrenal vein sampling; cosyntropin stimulation;
aldosterone producing adenoma; bilateral adrenal hyperplasia
1. Introduction
Primary aldosteronism (PA) is the most frequent cause of endocrine hypertension, with a
prevalence of around 6% in patients from primary care and up to 30% in referral units [1,2]. The majority
of affected patients have a sporadic form, either bilateral adrenal hyperplasia (BAH) or an aldosterone
producing adenoma (APA), that accounts for over 90% of all cases. Other forms of sporadic PA are
unilateral adrenal hyperplasia and adrenal producing carcinoma; familial forms account for less than
6% of all cases of PA [3].
Compelling evidence indicates that an excess of aldosterone exerts a detrimental role on the
cardiovascular system and affected patients display an increase in cardio and cerebrovascular
complications compared to patients with essential hypertension with similar risk profiles [2,4,5].
For this reason, an early diagnosis and specific treatment are important to revert target organ damage
and prevent cardiovascular events. The diagnosis of PA is made by a multistep process: (I) screening
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test, (II) confirmatory testing, and (III) subtype differentiation [6]. The last step is of fundamental
importance to distinguish between unilateral and bilateral PA, which require different therapeutic
approaches (unilateral laparoscopic adrenalectomy or medical therapy with a mineralocorticoid
receptor antagonist). According to the Endocrine Society (ES) Guideline, a subtype diagnosis comprises
adrenal CT scanning and adrenal venous sampling (AVS), a demanding procedure that requires an
expert and dedicated radiologist. Despite recent expert consensus, intended to address several issues
concerning performance and interpretation [7,8], AVS remains a poorly standardized procedure across
centers. This issue, together with reports [9,10] indicating high complication rates, has fostered
several attempts to develop clinical and biochemical prediction models of unilateral PA, “ancillary”
hormonal testings, or innovative targeted imaging techniques to overcome the need for AVS, at least
in a proportion of patients, and to use this procedure in patients with a high probability of unilateral
PA. In this manuscript, we critically review AVS performance in comparison with alternative tests or
clinical criteria in PA subtype diagnosis.
2. Comparison of AVS with Imaging Techniques
Adrenal CT scanning and magnetic resonance (MR) are the imaging techniques more commonly
used to evaluate adrenal morphology in PA patients [6]. According to the ES Guideline, adrenal CT
scanning is mandatory before AVS to evaluate adrenal morphology, abdominal venous drainage, and
exclude an adrenal carcinoma, but its sensitivity and specificity for subtype differentiation is poor
and does not exceed 87% and 71%, respectively, even when evaluated by an expert and dedicated
radiologist [11]. Although early studies suggested that imaging techniques were useful to locate
APAs [12], it became evident that CT and MR results were often discordant with AVS for the subtype
diagnosis of PA. The diagnostic accuracy of imaging techniques is hampered by intrinsic limitations of
the procedures, such as a suboptimal spatial resolution and a lack of functional data, that result in a
failure to identify micro APAs (less than 1 cm) or unilateral adrenal hyperplasia, and to differentiate
between APA and non-functioning adrenal incidentaloma [13,14].
An extensive systematic review [15] evaluating 950 patients from 38 different studies, reported
that CT/MR-based diagnoses were discordant with AVS results in 37.8% of patients. Following a
diagnosis by CT/RM imaging, 14.6% of patients would have been incorrectly identified as unilateral
PA and adrenalectomized (compared to the AVS diagnosis of bilateral aldosterone production);
CT/MR imaging would have also incorrectly diagnosed bilateral PA in 19.1% of patients (with AVS
demonstrating unilateral aldosterone production), thereby negating the possibility of a cure for PA
and hypertension. Even more importantly, an adrenalectomy would have been performed on the
wrong side in 3.9% of cases (i.e., contralateral to the site of aldosterone hypersecretion). When AVS
demonstrated unilateral aldosterone secretion in disagreement with the CT/RM results, imaging
techniques showed bilateral abnormalities in 39.9% of patients, no abnormalities in 30.9% of patients
and abnormalities in the opposite side compared to the AVS results in 17.0% of cases (in the remaining
cases, the exact result of the imaging technique was indicated as bilateral forms without further
indications) [15].
AVS is therefore considered as the gold standard test for PA subtype diagnosis; however,
the evidence for its superiority over adrenal imaging in terms of the clinical outcomes after an
adrenalectomy is limited. To this aim, Dekkers et al. designed a three-year randomized control
trial aimed at comparing two groups of CT- and AVS-based management in patients with confirmed
PA [16]. A total of 184 PA patients completed the follow up (92 received CT-based treatment and
92 AVS-based treatment) and were included in the study. The patients were evaluated according to an
intention-to-diagnose analysis and, after one year, there was no difference between the two groups
in the intensity of drug treatment required to obtain a target blood pressure, biochemical cure rate,
health-related quality of life, and adverse events. Of note, after a unilateral adrenalectomy, a total of
14 patients (15%), nine in the CT subgroup (20%) and five (11%) in the AVS subgroup (p = 0.25), showed
persistent PA; the authors concluded that both CT scanning and AVS are imperfect tests to identify the
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patients who are suitable for an adrenalectomy. Some concerns about the design of the study and the
application of the results to all patients with PA were raised [17,18]. The inclusion criteria comprised a
confirmed PA diagnosis and resistant hypertension or spontaneous/diuretic-induced hypokalemia.
Using these criteria, patients with the most severe PA and thus with a high probability of unilateral
PA were selected [18]. In addition, the study was designed to detect a 0.8 difference in the defined
daily dose between the two groups, but the real power of the study was inferior if only the patients
undergoing an adrenalectomy were considered [18]. It has been shown that a CT-based and AVS-based
diagnosis corresponds in 62% of cases [15]: therefore, the effective number of candidate patients for an
adrenalectomy in which a different diagnostic approach would have led to a different outcome, is not
likely to be greater than 35 individuals. Finally, a previous study [19] reported that an adrenalectomy
could also improve blood pressure levels in a significant proportion of BAH patients, reducing the
possibility to detect outcome differences in a relatively small cohort of patients. In conclusion, the low
power of the study does not allow one to draw any definitive conclusion or to generalize the results
to all PA patients. Further studies are warranted, and in the meanwhile, affected patients should not
be denied an AVS procedure, which remains the most reliable means to refer them for a unilateral
adrenalectomy or medical therapy.
3. Patients in Which AVS Can Be Avoided
Despite being the “gold standard” test to distinguish between unilateral and bilateral PA [6], AVS
remains a costly and challenging procedure, and is only routinely available in some tertiary referral
centers worldwide [20].
ES guidelines [6], despite the low amount of available evidence, suggest that in patients with the
following characteristics: (I) younger than 35 years, (II) severe PA phenotype (e.g., plasma aldosterone
concentration (PAC) > 30 ng/dL and spontaneous hypokalemia), and (III) CT scan showing a unilateral
adenoma with a normal contralateral adrenal gland, AVS can be avoided and it is possible to directly
proceed to a unilateral adrenalectomy [6,21,22].
However, the number of patients with PA who could avoid AVS according to these clinical criteria
is only about 10% [23]. For these reasons, considerable effort has been devoted to identify sensitive
and specific scores or ancillary hormonal tests to predict the lateralization of aldosterone production
and safely refer patients with PA to surgery without performing AVS or to limit the number of AVS
procedures. Küpers et al. reported that the combination of a solitary nodule on a CT scan and low
serum potassium (<3.5 mmol/L) or an estimated glomerular filtration rate ≥100 mL/min/1.73 m2, has
a 100% specificity for APA diagnosis [23]. However, the number of patients included in the analysis
was relatively small and subsequent studies on larger cohorts [21,24] did not confirm the results.
The sensitivity and specificity of the currently available clinical scores used to predict unilateral PA are
summarized in (Table 1).
Table 1. Sensitivity, specificity, and accuracy of the clinical scores and alternative tests currently
available to predict unilateral (or, when indicated, bilateral) PA.
Test/Clinical Score Sensitivity Specificity Accuracy Reference
Age < 40 and unilateral adrenal nodule > 1 cm
with normal contralateral adrenal gland [13]
n.a. 100% n.a. [11]
68% 83% 71% [21]
71% n.a. n.a. [22]
18% 100% 54% [23]
Age < 35 and unilateral adrenal nodule > 1 cm
with normal contralateral adrenal gland 100% n.a. n.a. [22]
Typical Conn’s adenoma, serum K+ <
3.5 mmol/L and/or eGFR ≥
100 mL/min/1.73 m2
53% 100% 74% [23]
46% 80% 58% [21]
39% 89% 56% [24]
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Table 1. Cont.
Test/Clinical Score Sensitivity Specificity Accuracy Reference
Typical Conn’s adenoma, serum
K+ < 3.5 mmol/L and/or eGFR ≥
100 mL/min/1.73 m2 and age < 40 years
59% 100% 68% [21]
Serum K+ ≤ 3 mmol/L and PAC ≥ 25 ng/dL
and/or urinary aldosterone greater ≥
30 µg/24 h (+stage III hypertension)
32% (23%) 95% (97%) 67% (64%) [11]
No adrenal nodule, serum K+ ≥ 3.5 mmol/L,
ARR post-captopril < 490 #
50%–67%
(7 points–5 points)
100%–94%
(7 points–5 points)
75%–80%
(7 points–5 points) [25]
Posture stimulation test
n.a. n.a. 85% [26]
64% 70% 67% [11]
44%–56%
(1 and 4 h respectively)
71%–75%
(1 and 4 h respectively) 52%–62% [27]
70% 79% 75% [28] (Torino)
51% 78% 69% [28] (Brisbane)
71% 100% 41% [29]
35% 100% 46% [29] *
ACTH stimulating test
91% 81% 90% [30]
83% (to predict BAH) 88% (to predict BAH) 84% [31]
Steroid profiling 83% 76% 80% [32]
Urinary 18OHF > 510 µg/24 h 35% 100% 84% [33]
Plasma 18oxoF > 4.7 ng/dL 83% 99% 92% [34]
Serum 18OHB > 100 ng/dL n.a. n.a. 82% [26]
Serum PTH > 80 ng/L 74% 82% 76% [35]
NP-59 scintigraphy scan n.a. n.a. 72% [26]
11C-metomidate PET-CT 76% 87% 80% [36]
PAC = plasma aldosterone concentration; eGFR = extimated glomerular filtration rate; ARR = aldosterone to renin
ratio; PTH = parathyroid hormone; NP-59 = [6β131I]iodomethyl-19-norcholesterol; n.a. = not available; # Scoring
system for the diagnosis of bilateral PA calculated as follows: no adrenal nodule at adrenal CT scanning, 3 points;
serum K+ ≥ 3.5 mmol/L, 2 points; aldosterone to renin ratio (ARR) post-captopril < 490 pg/mL/ng·mL·h−1,
2 points; * Postural response of 18OHB was evaluated.
When a CT scan, evaluated by an experienced radiologist, displays bilaterally normal adrenal
glands, AVS demonstrates bilateral aldosterone secretion in 95% of patients [11]. The treatment of these
patients with mineralocorticoid receptor antagonist (MRA) without AVS performance, is a reasonable
option, especially in centers where AVS is not readily available.
A recent study [30] evaluated the usefulness of the administration of intravenous ACTH (1-24)
before measuring the plasma aldosterone concentration in the peripheral vein. An ACTH stimulation
test (with a cut off value of 37.9 ng/dL for plasma aldosterone level) predicted the presence of unilateral
PA with a sensitivity and a specificity of 91.3% and 80.6%, respectively.
18-hydroxycortisol and 18-oxocortisol, also known as hybrid steroids, are synthesized
by aldosterone synthase using 11-deoxycortisol as a substrate (although 18OHF can also be
produced by 11β-hydroxylase), and have been detected at very high levels in some familial
forms [37,38]. 18-hydroxycorticosterone is a minor steroid synthesized by aldosterone synthase from
deoxycorticosterone; 18-hydroxycorticosterone is higher in individuals with APA than in BAH patients
and it has been proposed, since the late 1970s, as a biochemical marker to distinguish between unilateral
and bilateral aldosterone production. In support of this hypothesis, a further study demonstrated that
serum 18-hydroxycorticosterone, serum and urinary 18-hydroxycortisol, and 18-oxocortisol are higher
in patients with APA than in patients with BAH [33]. Moreover, plasma 18-oxocortisol (measured
by LC/MS/MS) above 6.1 ng/dL, together with a plasma aldosterone concentration higher than
32.7 ng/dL, was found in 84% of APA patients, but in none of the BAH cases [34]. In a retrospective
study (79 patients with unilateral PA), a peripheral venous steroid biomarker panel correctly classified
the APA genotype in 92% of cases [39]. Patients with APA carrying KCNJ5 mutations displayed
markedly elevated concentrations of the hybrid steroids 18-oxocortisol and 18-hydroxycortisol in the
peripheral plasma, which is presumably caused by the underlying histology of these adenomas with a
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predominant composition of zona fasciculata-like cells and an increased expression of CYP17A1 [40,41].
APA carrying KCNJ5 mutations [42] account for nearly 40% of sporadic adenomas [43], a frequency
that increases to 73% in populations from East Asia [44]. This high prevalence contributes to the
potential utility of steroid profiling for subtype differentiation in PA and could be responsible for the
high success rate of 18-oxocortisol measurements for distinguishing patients with APA in a study from
Japan, where the prevalence of KCNJ5 mutations is notably high [34].
Similarly, Eisenhofer et al. [32] proposed that the use of the steroid profiling in peripheral blood
could be useful to reduce the number of AVS, through the identification of patients with a high
probability of BAH, which were correctly identified in 76% of the cases.
Many alternative imaging tests have been proposed for the subtype diagnosis of PA, even though
none of them currently exhibit an adequate sensitivity and specificity to be relied on to refer PA patients
for a unilateral adrenalectomy. 6β-131iodomethyl-19-norcholesterol (NP-59) scanning, performed
under dexamethasone suppression, may correlate the anatomical findings with functional features.
However, it is not sensitive enough to detect a small APA (<1.5 cm), it is not widely available and,
therefore, does not play a significant role in subtype differentiation [6].
11C-metomidate positron emission tomography (PET)-CT scanning has been recently proposed
as an alternative test for PA subtyping, with a sensitivity of 76% and a specificity of 87% compared
to AVS [36]. Metomidate is a potent inhibitor of CYP11B1 (11β-hydroxylase), which is involved
in the last step of cortisol synthesis, and CYP11B2 (aldosterone synthase), the main regulator of
aldosterone synthesis. The administration of exogenous glcorticoid (dexamethasone) before the
procedure significantly reduces CYP11B1 expression in a normal adrenal gland, increasing the
“contrast” between the APA and normal adrenal tissue [45]. The major limitation of a wide use of this
procedure is the necessity of an on-site cyclotron, because of the very short half-life of carbon-11 [36].
To this regard, some authors are currently exploring alternative tracers with a longer half-life [46].
Abe et al. [47] recently synthesized a novel radiolabeled tracer (18F-CDP2230), displaying a lower
affinity for CYP11B2 and CYP11B1 compared to 11C-metomidate, but a relatively higher selectivity for
CYP11B2 over CYP11B1. The higher selectivity for CYP11B2, the longer half-life, and the absence of
the requirement for dexamethasone pretreatment, are the three main advantages of 18F-CDP2230 over
metomidate. Human in vivo studies are needed to further evaluate its specificity and sensitivity in
PA subtyping.
The presence of familial hyperaldosteronism type I and III, in which the disease is always bilateral,
should be ruled out before AVS. The diagnosis of familial hyperaldosteronism type I made by the
demonstration of the hybrid CYP11B1/CYP11B2 gene, should be considered in all PA patients with
an early onset of PA (<20 years), a family history of PA, or a family history of stroke at a young
age [6]. Familial hyperaldosteronism type III, a rare but particularly severe form of PA, due to germline
KCNJ5 mutations [42], should be considered in all PA patients with an onset at a very young age
(<20 years) [6]. Recently, germline mutations in the CACNA1H gene, encoding for the alpha subunit of
a L-type voltage-gated calcium channel (Cav3.2), were discovered to be responsible for a novel form of
familial hyperaldosteronism (type IV) with an incomplete penetrance. However, Zennaro et al. [48]
reported a single case of a CACNA1H germline mutation identified in one patient who underwent an
adrenalectomy, followed by a complete biochemical and clinical response (AVS was not performed).
To this regard, further insights into the familial hyperaldosteronism type IV spectrum are currently
needed to define the best diagnostic and therapeutic approach in this familial form of PA.
4. AVS Methodology
AVS is performed via a percutaneous femoral vein approach and the adrenal veins are cannulated
using a fluoroscopy guide (Supplementary multimedia file). The left adrenal vein is usually easily
cannulated, because it generally drains directly into the left renal vein [49], while the cannulation of
the shorter and smaller right adrenal vein, which usually drains directly into the inferior vena cava,
can be difficult. Despite being a challenging procedure, the complication rate associated with AVS is
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very low (0.61%) [20]; adrenal haemorrhage, which is the most serious complication, has a favourable
outcome in the majority of patients, causing minor or no permanent effects on adrenal function [50].
Other AVS protocols are described below.
5. Bilaterally Simultaneous vs. Sequential Cannulation
The main proposed advantage of the simultaneous cannulation of the adrenal veins is to
avoid oscillations of aldosterone and cortisol secretion, which could artificially modify the gradient
of aldosterone production between the two adrenals if the procedure is performed under basal
conditions [51]. On the other hand, simultaneous AVS is more invasive (requiring the insertions of two
catheters) and demanding than the sequential technique. Recently, a retrospective study [52] comparing
simultaneous and sequential AVS (with a 5 min time-gap between cannulations) under basal conditions,
demonstrated no significant differences in the selectivity and lateralization indices. However, whether
long time-gaps (e.g., during a difficult cannulation of one adrenal gland) could significantly modify
the AVS results is still unknown. This study demonstrated that sequential cannulation displays the
same accuracy compared with simultaneous cannulation, even in an unstimulated procedure, as long
as the time between the cannulation of the two adrenal veins remains relatively short.
6. Segmental AVS
Some authors propose segmental AVS as a way to refer PA patients for a selective nodulectomy,
instead of the total resection of the adrenal gland [53]. This is particularly relevant to enable the
surgical cure of patients with bilateral APA and in patients with APA in the remaining adrenal gland
after a contralateral adrenalectomy [53].
In segmental AVS, samples are collected from tributaries of the central adrenal vein and compared
to each other to provide more detailed information regarding the location of the secreting nodule
within the gland. The main disadvantages of this technique are that segmental AVS is technically
even more demanding, time-consuming and expensive [53]. Furthermore, in two case series, an
extravasation of the iodine contrast occurred in 12.6% [53] and in 16% [54] of patients undergoing
segmental AVS, making this complication more common than in central AVS [53].
7. Cosyntropin Stimulation
ACTH 1-24 is a synthetic derivate of the adrenocorticotropic hormone (ACTH), whose infusion
during the AVS procedure was introduced by Melby et al. in 1967 [55]. Two major protocols of ACTH
(1-24) administration are currently used: (I) ACTH (1-24) continuous infusion (50 µg/h, starting 30 min
before the first sampling), and (II) ACTH bolus (250 µg [10 IU]).
The main advantage of the ACTH (1-24) infusion is to maximise the cortisol gradient between
the adrenal and peripheral veins, to minimise aldosterone fluctuations, and to maximise aldosterone
production from an APA [8,13]. Furthermore, ACTH (1-24) infusion is necessary for patients at a
high risk of allergic reaction, in which steroidal prophylaxis is required, in patients with subclinical
hypercortisolism (to stimulate cortisol production from the contralateral gland, which is expected
to be suppressed), and when the AVS procedure is not performed in the early morning, when
cortisol secretion in higher. Moreover, in centres with low rates of success of adrenal cannulation,
the ACTH (1-24) infusion can significantly improve the percentage of successful procedures [56–58].
The main criticism of the ACTH (1-24) infusion is that it could potentially stimulate aldosterone
secretion from the contralateral adrenal gland (in respect to an APA) and therefore reduce the
lateralisation index [59]. A multicenter retrospective study [58] showed a concordant diagnosis
between ACTH (1-24) stimulated and basal AVS in 88% of cases with continuous infusion protocol
and 78% with ACTH (1-24) intravenous bolus. Interestingly, the reproducibility of the diagnosis was
lower with more permissive criteria of lateralisation, increasing the percentage of patients potentially
susceptible to inappropriate treatment [58]. El Ghorayeb et al. found that basal and post-ACTH AVS
results were discordant in 28% of cases, with the great majority of lateralized procedures under basal
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conditions becoming bilateral after the administration of ACTH (1-24). However, the results might
have been affected by the fact that the authors chose a higher LI cut-off for the ACTH-stimulated
procedures compared to the basal ones (LI ≥ 4 and LI ≥ 2, respectively), despite a slight decrease in
the median LI after ACTH (from 7 to 6.7) [56]. In addition, Wolley et al. suggested that ACTH (1-24)
administration might be useful in those cases with bilaterally suppressed aldosterone production
(i.e., an IL ratio lower than the peripheral on both sides) [57].
In conclusion, cosyntropin-stimulated AVS displays a similar performance and diagnostic
accuracy compared with unstimulated AVS. Cosyntropin infusion could be the preferred strategy in
centres with a lower success rate of cannulation.
8. Improving the Success Rate
A wealth of studies [11,13,20,49,60,61] have demonstrated that an expert and dedicated
radiologist is a key factor for significantly improving sampling success. Therefore, gathering AVS
procedures in one single centre per geographical area is important to further reduce the number of
unsuccessful studies.
Other than ACTH (1-24) administration, another strategy to improve performances in centres with
a low success rate is through the use of a rapid cortisol assay, performed during the AVS procedure.
Measurements of cortisol can be done in the central laboratory of the hospital [62–64] or inside the
radiology room using a benchtop analyser [65]. The latter method, performed with a reliable cortisol
immunofluorimetric assay [65] or with immunochromatography and gold nanoparticles [66], more
rapidly provide information to the radiologist on the position of the catheter tip. Rapid cortisol
measurements enable the radiologist further attempts to correctly cannulate the adrenal veins,
and allow self-training of the radiologist to progressively increase the percentage of successful
procedures [62].
Dyna computed tomography performed during the AVS procedure, is an alternative method to
evaluate the correct catheter tip positioning and was recently proposed by Chang et al. [67], allowing a
correct repositioning of the catheter tip in 12% of cases.
9. AVS Interpretation Criteria
The selectivity index (SI) is defined as the cortisol ratio between an adrenal vein and a peripheral
vein and it is used to confirm the adequacy of adrenal vein catheterization (Table 2). Most centres
use an SI cut-off of at least two to three under basal conditions and three to five under ACTH (1-24)
stimulation, with a minority of the centres using more permissive SI criteria under a basal condition
(≥1.1 or 1.36) [20].
In order to identify the best SI cut-off value in the basal condition, Mulatero et al. [68] evaluated
the concordance of the AVS results in patients who underwent two AVS procedures on two separate
occasions, because the first one was unsatisfactory. The most permissive SI criteria (SI ≥ 1.1) provided
a concordant diagnosis in only 35% of patients and intermediate criteria (SI ≥ 2.0) in only 50% of
patients. An SI > 2.7 was necessary to achieve 100% reproducibility in the same patients.
Considering an SI cut-off of five (under ACTH (1-24) stimulation) as the reference standard,
Mailhot et al. [69] investigated the best SI cut-off value for AVS performed under a basal condition.
An SI cut-off of two provided the highest sensitivity (70.8%) with 100% specificity. Interestingly, they
proposed the use of the aldosterone ratio (defined as the ratio between the aldosterone levels in the
adrenal vein over the peripheral vein) combined with the cortisol ratio to further improve the SI
sensitivity in the basal condition. AVS was considered satisfactory if at least one of the two ratios met
the SI criteria. An SI cut-off of two for both (aldosterone and cortisol) ratios provided the greatest
sensitivity (88.3% of procedures) with a 100% specificity.
The lateralization index (LI) is defined as the ratio between the aldosterone/cortisol level in the
dominant side and the aldosterone/cortisol level in the contralateral gland, and is used to determine
the final subtype diagnosis in the majority of centres (Table 2). Currently, there is not a wide consensus
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on the optimal LI cut-off to better differentiate between unilateral and bilateral forms. Although a
LI ≥ 4 is deemed to be diagnostic of unilateral PA in most units, some centres adopt more permissive
criteria (LI > 3 more commonly and LI > 2 in few centres).
Table 2. Adrenal vein sampling indices, definition, clinical significance, and recommended cut-off in
clinical practice.
Index Measurement Clinical Significance Suggested Cut-Off
Selectivity index (SI) Cortisoladrenal vein/Cortisolperipheral vein
Successful adrenal
vein cannulation
SI > 3 for basal studies
SI > 5 for ACTH (1-24)
stimulated AVS
Lateralization index (LI) (Aldosterone/Cortisol)dominant adrenal vein/(Aldosterone/Cortisol)non dominant adrenal vein
Lateralization of
aldosterone production
LI > 4 for unilateral PA
LI < 3 for bilateral PA
3 < LI < 4 grey zone
Ipsilateral ratio (ILR)
(Aldosterone/Cortisol)dominant adrenal vein/
(Aldosterone/Cortisol)peripheral vein
Gradient of aldosterone
production between the
adrenal vein and a
peripheral vein
ILR > 2 is required in
some centers together
with CLR < 1 to define
unilateral PA
Contralateral ratio (CLR)
(Aldosterone/Cortisol)non dominant adrenal vein/
(Aldosterone/Cortisol)peripheral vein
Suppression of aldosterone
production in the
non-dominant side
CLR < 1 can be used as
additional criteria for the
interpretation of
suboptimal studies
Absolute contralateral
aldosterone ratio [56]
Aldosteronenon dominant adrenal vein/
Aldosteroneperipheral vein
Absolute suppression of
aldosterone production in the
non-dominant side
<1.5 predicts outcomes
after adrenalectomy
In a recent informative study, AVS performed in patients with a positive screening test for PA
but a negative confirmatory testing, demonstrated that eight out of 40 patients had an LI comprised
between two and four, and no patients showed an LI greater than 4 suggesting that 2 ≤ LI ≤ 4 should
be cautiously interpreted [70].
In some centres, an ipsilateral ratio (IR) > 2, together with a contralateral aldosterone suppression
(defined as CL ratio (CR) < 1, Table 2), are used instead of LI to determine whether the disease
is unilateral [71]. However, the clinical significance of contralateral suppression and its impact on
postoperative outcomes after a unilateral adrenalectomy is still controversial. Monticone et al., in a large
multicenter study, reported no significant differences in terms of the biochemical and clinical response
after an adrenalectomy between patients with and without contralateral aldosterone suppression and
an LI ≥ 4 [72]. The clinical significance of CR < 1 in patients with a 2 < LI < 4 was investigated by
Umakoshi et al. in a small cohort of 29 patients [73]. The authors reported a significant difference
in terms of the overall cure rate of PA between patients with and without contralateral suppression
(81% versus 31%), pointing out a possible major usefulness of CR in evaluating the “grey zone” of AVS
results. On the other hand, Wolley et al. observed a greater proportion of biochemical cure and a lower
number of antihypertensive drugs after an adrenalectomy in patients displaying CR < 1; however,
differences between the studies in terms of the definition of lateralisation and the selection of patients
could partially account for the different results [74].
In addition, some experts suggest that CR can be useful when the radiologist fails to catheterize
one of the adrenal veins (more often the right adrenal vein) and the opposite site is suppressed,
suggesting the possible presence of unilateral PA [75,76]. However, it must be taken into account that
up to 30% of BAH patients show a suppressed non dominant A/C ratio, indicating that a CR < 1 is not
specific enough to diagnose unilateral PA and refer patients for surgery [13].
More recently, El Ghorayeb et al. [56] did not observe significant differences in the blood pressure
response to an adrenalectomy between patients with and without contralateral suppression; these
authors suggest the use of the adrenal aldosterone/peripheral aldosterone (without cortisol correction)
to predict the clinical and biochemical response to an adrenalectomy.
Finally, a plasma metanephrine measurement was recently proposed as a useful tool to evaluate
the selectivity and lateralisation during AVS [71,77]. The main advantage of a metanephrine
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measurement is that it avoids cortisol fluctuation (metanephrine is produced continuously from
epinephrine leaking from storage vesicles within adrenal medullary cells), it is not influenced by
ACTH (1,24) stimulation, and the gradient between the adrenal and peripheral sample is significantly
higher [77]. In fact, metanephrine is produced almost exclusively in the adrenals [78] and is rapidly
cleared from the circulation, allowing a greater adrenal/peripheral ratio compared to the cortisol
ratio. Furthermore, a metanephrine assay may be particularly useful in some specific situations
in which a cortisol assay could give misleading information (e.g., the co-existence of subclinical
hypercortisolism) [79]. In conclusion, an LI ≥ 4 should be considered diagnostic of unilateral PA in
all patients, whereas an LI < 2 indicates a bilateral form. An LI comprised of between two and four
can be considered as a “grey zone” and other AVS parameters (CR and IR), clinical and biochemical
features, and adrenal morphology may help to reach the final decision on the preferred therapeutic
approach (an example of the AVS procedure with an interpretation of hormonal data is provided as a
Supplementary multimedia file).
10. Conclusions
The subtype diagnosis of PA is challenging and the optimal strategy is still debated. Despite being
costly and invasive, AVS is still the “gold standard” test for a subtype diagnosis, as recommended
by guidelines [6,80]. In the last few years, many efforts have been devoted to identifying alternative
tests to substitute or to reduce the number of patients undergoing AVS. Nevertheless, none of
these tests have demonstrated an adequate accuracy to substitute AVS in a significant amount of
patients. Further multicentric prospective studies are warranted to identify a common and recognized
AVS protocol.
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